Date
- Monday, 23 November 2015, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
This EMA workshop will bring together experts and stakeholders to discuss the utility of pharmacokinetic (PK) and pharmacodynamic (PD) measurements in the clinical use of the new direct oral anticoagulants (DOACs) and whether those could enhance the benefit-risk profile of these medicines by further reducing the risk of major bleedings while maintaining or improving the protection against thromboembolic events. The objectives of the workshop are to improve the understanding of the clinical use of DOACs, issues in relation to PK and PD measurements as well as priorities in future research.
Documents
Programme - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (103.79 KB - PDF)
Workshop - the role of pharmacodynamic and pharmacokinetic measurements in the use of direct oral anticoagulants: Background document
English (EN) (135.01 KB - PDF)
Proceedings of the workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (133.43 KB - PDF)
List of participants - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (122.38 KB - PDF)
Presentation - DOACs: the patient perspective (Christine Dehn)
English (EN) (336.78 KB - PDF)
Presentation - Challenging patients on DOACs and need for monitoring (Menno Huisman)
English (EN) (1.04 MB - PDF)
Presentation - Management of DOAC in clinical praxis (Peter J Svensson)
English (EN) (5.08 MB - PDF)
Presentation - What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) (Marie Louise S. Christiansen)
Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (285.33 KB - PDF)
Presentation - Session 2: What can we do now and what are the gaps in our knowledge? The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) (Antonio Gà³mez-Outes)
The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)
English (EN) (1.03 MB - PDF)
Presentation - Session 3: the analytical part - Measuring the concentration of the direct thrombin inhibitor (dabigatran etexilate) (Franà§ois Mullier)
Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (1015.5 KB - PDF)
Presentation - Measuring concentrations of Rivaroxaban, Apixaban, Edoxaban: methods and challenges (Steve Kitchen)
Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (517.45 KB - PDF)
Presentation - NOAC future perspectives: academic perspective (Hugo ten Cate)
Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (2.42 MB - PDF)
Presentation - Future perspectives: how to better use the available data, how to fill the gaps in our knowledge about PK/PD, future ways on how knowledge can be obtained (Jà¶rg Kreuzer)
English (EN) (252.1 KB - PDF)
Presentation - Industry perspective: Bayer/Janssen (Scott D. Berkowitz)
English (EN) (874.78 KB - PDF)
Presentation - Industry perspective: Pfizer - Eliquis® (apixaban)
Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants
English (EN) (228.82 KB - PDF)
Presentation - Session 4: future perspectives - What could be done? Industry perspective (Daiichi Sankyo)
English (EN) (371.72 KB - PDF)
Multimedia
Video recording
A video recording is now available.
To view use the 'Multimedia' tab.